TransMedics Group, Inc.

Annual Trend FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Net income (loss) ($23.8m) ($33.5m) ($28.7m) ($44.2m) ($36.2m) ($25.0m) $35.5m $190.3m
Depreciation and amortization expense $769k $1.2m $1.6m $1.8m $3.5m $8.2m $19.8m $27.2m
Deferred taxes ($1.7m) ($83.5m)
Non-cash interest expense and end of term accretion expense $177k $475k $511k $540k $465k $2.1m $3.1m $3.1m
Operating lease liabilities $236k $255k ($1.6m) ($2.3m) ($2.9m)
Operating lease liabilities arising from obtaining right-of-use assets $2.2m $1.5m $795k
Stock-based compensation expense $144k $854k $2.4m $6.9m $10.3m $19.8m $33.2m $36.9m
Acquired in-process research and development expenses $27.2m
Non-cash lease expense $829k $717k $1.0m $1.6m $2.1m
Unrealized foreign currency transaction (gains) losses $150k $200k ($1.1m) $928k $1.1m ($342k) $665k ($1.6m)
Loss on disposal of fixed assets $17k $80k
Accounts receivable ($2.5m) ($3.2m) ($218k) $840k ($21.7m) ($33.8m) ($34.3m) $13.9m
Inventory ($2.7m) ($4.1m) ($1.7m) ($4.9m) ($8.0m) ($28.1m) ($8.4m) ($7.7m)
Prepaid expenses and other current assets ($1.4m) $250k ($769k) ($3.2m) $2.5m ($2.1m) ($6.3m) ($3.8m)
Other non-current assets ($54k) ($149k) ($23k)
Accounts payable $164k $3.4m ($5.8m) $5.1m ($3.3m) $7.0m ($1.4m) ($19k)
Accrued expenses and other current liabilities $2.3m $2.5m $1.9m $4.9m $3.4m $14.2m $7.9m $17.7m
Deferred revenue $67k ($136k) $60k $7k $83k ($203k) $1.1m
Purchase of in-process research and development assets ($27.2m)
Proceeds from issuance of convertible senior notes, net of issuance costs paid of $14,620 $445.4m
Purchases of capped calls related to convertible senior notes ($52.1m)
Tax withholding payments related to net settlement of restricted stock units ($138k)
Purchases of property, plant and equipment included in accounts payable and accrued expenses $169k $1.2m $62k $2.5m $2.1m $1.8m
Conversion of convertible senior notes into common stock $4k
Cash $394.8m $336.6m $488.4m
Net cash provided by (used in) operating activities ($26.0m) ($32.3m) ($30.3m) ($28.9m) ($45.8m) ($13.0m) $48.8m $192.8m
Purchases of property, plant and equipment ($418k) ($165k) ($455k) ($3.5m) ($11.9m) ($151.8m) ($129.7m) ($59.3m)
Transfers of inventory to property, plant and equipment $1.4m $2.1m $1.2m $1.8m $2.1m $4.6m $5.8m $5.7m
Purchase of business, net of cash acquired ($14.9m) $441k
Net cash used in investing activities $12.3m ($60.5m) ($41.6m) $29.3m $54.5m ($194.0m) ($129.3m) ($59.3m)
Proceeds from issuance of common stock upon exercise of stock options $46k $202k $227k $974k $4.7m $6.2m $20.8m $13.7m
Proceeds from issuance of common stock in connection with employee stock purchase plan $357k $419k $509k $955k $2.1m $3.2m
Net cash provided by financing activities $22.1m $92.7m $75.5m $1.4m $167.9m $400.4m $22.9m $16.9m
Effect of exchange rate changes on cash and restricted cash ($82k) ($85k) $803k ($797k) ($1.0m) $193k ($536k) $1.3m
Net increase (decrease) in cash and restricted cash $8.3m ($149k) $4.5m $999k $175.6m $193.6m ($58.2m) $151.7m
Cash and restricted cash, beginning of period $20.7m $20.6m $25.1m $26.1m $201.7m $395.3m $337.1m $488.9m
Cash and cash equivalents $20.1m $24.6m $25.6m $201.2m $394.8m
Restricted Cash $500k $500k $500k $500k $500k $500k $500k
Cash paid for interest $2.4m $3.9m $3.5m $3.3m $3.3m $8.1m $11.3m $10.7m